

Sélection des publications 2012 de l'équipe 1

Arnaoty A, Pitard B, Bateau B, Bigot Y, Lecomte T.

Novel approach for the development of new antibodies directed against transposase-derived proteins encoded by human neogenes.

Methods Mol Biol 2012, 859 : 293-305

Cholez E, Debuyscher V, Bourgeois J, Boudot C, Leprince J, Tron F, Brassart B, Regnier A, Bissac E, Pecnard E, Gouilleux F, Lassoued K, Gouilleux-Gruart V

Evidence for a protective role of the STAT5 transcription factor against oxidative stress in human leukemic pre-B cells.

Leukemia 2012, 26 : 2390-2397

Crocchiolo R, Ciccolini J, El-Cheikh J, Fürst S, Castagna L, Granata A, Oudin C, Harbi S, Devillier R, Legall S, Ternant D, Paintaud G, Lacarelle B, Blaise D.

Successful treatment of a post-transplant ebv-related meningoencephalitis by intravenous rituximab monotherapy.

Leuk Lymphoma 2012, 53 : 2063-2065

Daguet A, Watier H.

[Serotherapy, among therapeutic innovations and scientific progress in the late 19th and 20th centuries].

[Article in French]

Rev Prat. 2012.62 : 1177-1781

Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F

Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.

JAMA 2012, 307 : 948-955

Lapalud P, Ali T, Cayzac C, Mathieu-Dupas E, Levesque H, Pfeiffer C, Balicchi J, Gruel Y, Borg JY, Schved JF, Granier C, Lavigne-Lissalde G.

The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII.

J Thromb Haemost 2012, 10 : 1814-1822

Lejeune J, Piègu B, Gouilleux-Gruart V, Ohresser M, Watier H, Thibault G.

FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.

MAbs 2012, 4 : 784-787

Lekpa FK, Poulain C, Wendling D, Soubrier M, De Bandt M, Berthelot JM, Gaudin P, Toussirot E, Goupille P, Pham T, Sellam J, Bruckert R, Paul M, Farrenq V, Claudepierre P; the Club Rhumatismes et Inflammation.

Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study.

Arthritis Res Ther 2012, 14 : R53

Leroux D, Canépa S, Viskov C, Mourier P, Herman F, Rollin J, Gruel Y, Pouplard C.

Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay.

J Thromb Haemost 2012, 10 : 430-436

Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M; Groupe D'études Thérapeutiques Des Affections Inflammatoires Digestives.

Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Gastroenterology 2012, 142 : 63-70

Magnant J, Ohresser M, Allanore Y, de Monte M, Lafosse-Marin M, Degenne D, Guilmot JL, Watier H, Diot E Association of Fcγ receptor IIIA variant with a subset of anti-topoisomerase I-positive patients in systemic sclerosis: a descriptive pilot study.

Rheumatol Int 2012, 32 : 2203-2207

Mariette X, Baron G, Tubach F, Lioté F, Combe B, Miceli-Richard C, Flipo RM, Goupille P, Allez M, Salmon D, Emilie D, Carcelain G, Ravaud P.

Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.

Ann Rheum Dis 2012, 71 : 1783-1790

Mulleman D, Ducourau E, Paintaud G, Ternant D, Watier H, Goupille P.

Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?

Joint Bone Spine 2012, 79 : 109-112

Paintaud G, Diviné M, Lechat P; participants of Round Table N°5 of Giens XXVII.

Monoclonal Antibodies for Therapeutic Use: Specific Characteristics of Clinical Development, Evaluation by the Agencies, and Long-term Monitoring of Safety.

Thérapie 2012, 67 : 329-337

Pham T, Bachelez H, Berthelot JM, Blacher J, Claudepierre P, Constantin A, Fautrel B, Gaujoux-Viala C, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Lequerré T, Marolleau JP, Martinez V, Masson C, Mouthon L, Puéchal X, Richette P, Saraux A, Schaeffer T, Soubrier M, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J.

Abatacept therapy and safety management.

Joint Bone Spine 2012, 79 Suppl 1 : 3-84

Pointreau Y, Commins SP, Calais G, Watier H, Platts-Mills TA.

Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis.

J Clin Oncol 2012, 30 : 334 ; author reply 335

Pouplard C, Cornillet-Lefebvre P, Attaoua R, Leroux D, Lecocq-Lafon C, Rollin J, Grigorescu F, Nguyen P, Gruel Y.

Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia.

Thromb Res 2012, 129 : 465-469

Rollin J, Pouplard C, Gratacap MP, Leroux D, May MA, Aupart M, Gouilleux-Gruart V, Payrastre B, Gruel Y.
Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia.
Blood 2012, 120 : 1309-1316

Samson G, García de la Calera A, Dupuis-Girod S, Faure F, Decullier E, Paintaud G, Vignault C, Scoazec JY, Pivot C, Plauchu H, Pirot F.
Ex vivo study of bevacizumab transport through porcine nasal mucosa.
Eur J Pharm Biopharm 2012, 80 : 465-469

Ternant D, Cartron G, Hénin E, Tod M, Girard P, Paintaud G.
Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.
Br J Clin Pharmacol 2012, 73 : 597-605

Ternant D, Mulleman D, Lauféron F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G.
Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.
Br J Clin Pharmacol 2012, 73 : 55-65